Statin use may have beneficial effects on overall survival (OS) and
disease-free survival (DFS) among patients with melanoma, according
to results of a systematic review and meta-analysis published in
Melanoma Research.
2024
IMA203 Displays Efficacy in Heavily Pretreated Melanoma
IMA203, a TCR-T agent targeting PRAME, was active and offered meaningful
progression-free survival (PFS) and overall survival (OS) outcomes in patients
with heavily pretreated melanoma, according to updated data from a phase 1b
study (NCT03686124) provided by Immatics NV.
Melanoma Incidence, Mortality Declining in Those Aged 30 to 49 Years
HealthDay News — For adults aged 30 to 49 years, there has been a decline in melanoma incidence and mortality, according to a study published online Sept. 8 in JAMA Dermatology to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
ESMO 2024: More than half of advanced melanoma patients treated with combination immunotherapy survive the disease for at least 10 years
Over half (52 per cent) of people diagnosed with advanced melanoma are now surviving the disease for ten years or more when they receive a combination immunotherapy treatment, according to a study led by researchers at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.